Open Clinical Trials
The Atlantic Clinical Cancer Research Unit (ACCRU) based in Halifax, Nova Scotia was formed in May of 2008.
Its mission is to provide as many cancer patients as possible with access to promising new drugs and treatment strategies. At any given time, the staff is co-ordinating 30 to 40 trials involving about 150 patients while following 400 or more patients who have completed clinical trials.
Listed below are the currently open trials that cancer patients may be eligible for as of December 13, 2011. If you have any questions regarding eligibility or referring your patients, please do not hesitate to call the ACCRU Manager at 902 473 2161.
ACTIVE CLINICAL TRIALS
BREAST CANCER
Adjuvant Breast Cancer:
N/A
Adjuvant Breast Cancer:
DCIS
A Randomized, Phase III Study of Radiation Doses and Fractionation Schedules for Ductal Carcinoma in Situ (DCIS) of the Breast
Metastatic Breast Cancer – Hormone Receptor Positive:
A Randomized, Double-Blinded Phase 2 Trial of Exemestane +/- MM-121 in Postmenopausal Women with Locally Advanced or Metastatic Estrogen Receptor Positive (ER+) and/or Progesterone Receptor Positive (PR+), HER2 Negative Breast Cancer
Metastatic Breast Cancer – HER2 Positive:
LPT11215 (HALT)
A Randomized, Phase III, Open-label Study of Lapatinib plus Trastuzumab versus Trastuzumab as Continued HER2 Suppression Therapy after Completion of First- or Second-line Trastuzumab plus Chemotherapy in Subjects with HER2-positive Metastatic Breast Cancer
Metastatic Breast Cancer – Triple Negative:
NCIC IND.197
A Phase II Study of Foretinib in Patients with Estrogen Receptor (ER), Progesterone Receptor (PR) and Human Epidermal Growth Factor Receptor 2 (HER2) Negative, Recurrent/Metastatic Breast Cancer
GASTROINTESTINAL CANCER
Adjuvant Colorectal Cancer:
N/A
Metastatic Colorectal Cancer:
IMCLONE
Open-label, Multi-Centre, Randomized, Phase II Study Evaluating the Safety and Efficacy of5‑FU/FA and Oxaliplatin (Modified FOLFOX‑6) in Combination with IMC‑1121B or IMC‑18F1 or without Investigational Therapy as Second Therapy in Patients With Metastatic Colorectal Cancer Following Disease Progression on First-line Irinotecan-based Treatment
Pancreatic Cancer:
N/A
Esophageal Cancer:
NCIC ES.2
A Randomized Phase III Study in Advanced Esophageal Cancer to Compare Quality of Life and Palliation of Dysphagia in Patients withRadiotherapy Versus Chemo-Radiotherapy
GENITOURINARY CANCER
Adjuvant Renal Cell Carcinoma:
VEG113387
A Randomized, Double-Blind, Placebo-Controlled Phase III Study to Evaluate the Efficacy and Safety of Pazopanib as Adjuvant Therapy for Subjects with Localized or Locally Advanced RCC Following Nephrectomy.
Metastatic Bladder Study
An Open-Label, Multicenter, Randomized Phase 2 Study Evaluating the Safety and Efficacy of Docetaxel in Combination with Ramucirumab (IMC-1121B) Drug Product or IMC-18F1 or Without Investigational Therapy as Second-line Therapy in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma of the Bladder, Urethra, Ureter, or Renal Pelvis Following Disease Progression on First-line Platinum-based Therapy.
Metastatic Renal Cell Carcinoma:
CTK1258A2302
An open-label, randomized, multi-center, Phase III study to compare the safety and efficacy of TKI258 versus sorafenib in patients with metastatic renal cell carcinoma after failure of anti-angiogenic (VEGF-targeted and mTOR inhibitor) therapies.
EORTC 30073/ CUOG
Randomized, Phase III Trial Comparing Immediate Versus Deferred Nephrectomy in Patients with Synchronous Metastatic Renal Cell Carcinoma
Localized Prostate Cancer – Low Risk:
N/A
Localized Prostate Cancer – Intermediate Risk:
RTOG 0815
A Phase III Prospective Randomized Trial of Dose- Escalated Radiotherapy with or without Short-Term Androgen Deprivation Therapy for Patients with Intermediate-Risk Prostate Cancer
Localized Prostate Cancer – High Risk:
ELDORADO (ELigard, Docetaxel and RADiOtherapy)
A Phase II Study of Chemo-hormonal Therapy and Radiation in High-Risk Prostate Cancer
Adjuvant Prostate Cancer:
NCIC PR.13 (RADICALS)
Radiotherapy and Androgen Deprivation in Combination after Local Surgery: A Randomized Controlled Trial in Prostate Cancer
Biochemical Recurrence:
N/A
Metastatic First-Line/Second-Line:
OGX-011-01
A Randomized Phase 3 Study Comparing Standard First-Line Docetaxel/Prednisone to Docetaxel/Prednisone in Combination with Custirsen (OGX-011) in Men with Metastatic Castrate Resistant Prostate Cancer
PREVAIL
A Multinational Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Oral MDV3100 in Chemotherapy-Naïve Patients with Progressive Metastatic Prostate Cancer Who Have Failed Androgen Deprivation Therapy
GYNAECOLOGICAL CANCER
Adjuvant Endometrial Cancer:
NCIC EN.7
A Randomized, Phase III Trial Comparing Concurrent Chemoradiation and Adjuvant Chemotherapy with Pelvic Radiation Alone in High Risk and Advanced Stage Endometrial Carcinoma
Metastatic Endometrial Cancer:
CA163-196
A Phase III Open Label, Randomized, 2 Arm Study of Ixabepilone Administered Every 21 Days Versus Paclitaxel or Doxorubicin Administered Every 21 Days in Women with Advanced Endometrial Cancer Who Have Previously Been Treated with Chemotherapy
Ovarian Cancer:
NCIC OV.21
A Phase II – III Study of IP Plus IV Chemotherapy Versus IV Carboplatin + Paclitaxel in Patients with Epithelial Ovarian Cancer Optimally Debulked at Surgery Following Neoadjuvant IV Chemotherapy
Vulvar Cancer:
GROINNS
GROningenInternational Study on Sentinal Nodes in Vulvar Cancer (GROINSS-V) II: An ObservationalStudy
HEAD AND NECK CANCER
RTOG 0920
A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer
NEUROLOGICAL CANCER
NCIC CE.6
A Randomized Phase III Study of Temozolomide and Short-Course Radiation versus Short-Course Radiation Alone in the Treatment of Newly Diagnosed Glioblastoma Multiforme in Elderly Patients.
NCIC IND.204:
A Phase II Study of PX-866 in Patients with Glioblastoma Multiforme at the Time of First Relapse or Progression
MELANOMA
NCIC IND.202
A Randomized Phase II Study of Interleukin-21 (rIL-21) Versus Dacarbazine (DTIC) In Patients with Metastatic or Recurrent Melanoma
Metastatic Melanoma:
Roche - MO25515
An Open-Label, Multicenter Expanded Access Study of RO5185426 in Patients with Metastatic Melanoma
NEUROENDOCRINE TUMORS
NCIC-NEC.2
Randomized Phase II Study of Everolimus Alone versus Everolimus Plus Bevacizumab in Patients with Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumours
SOM2303
A Multicentre, Randomized, Blinded Efficacy and Safety Study of Pasireotide LAR versus Octreotide LAR in Patients with Metastatic Carcinoid Tumors Whose Disease-Related Symptoms are Inadequately Controlled by Somatostatin Analogues
THORACIC CANCER
Advanced NSCLC
A Double Blind Placebo Controlled Randomized Trial of PF-804 in Patients With Incurable Stage IIIB/IV Non-small Cell Lung Cancer After Failure of Standard Therapy for Advanced or Metastatic Disease
Adjuvant NSCLC:
NCIC BRC.2
Phase III Randomized Trial of Adjuvant Chemotherapy with or without Bevacizumab for Patients with Completely Resected Stage 1B (> 4 cm) - IIIA Non-Small Cell Lung Cancer (NSCLC)
